Open-Label, Biomarker-Directed Platform Study In Nsclc Patients Who Progressed On An Anti-Pd-(L)1-Containing Therapy (Hudson)

JOURNAL OF THORACIC ONCOLOGY(2019)

引用 0|浏览0
暂无评分
关键词
metastatic NSCLC,biomarkers,immunotherapy resistance
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要